Microbot Medical Inc Dossier - Source-backed chat

Microbot Medical Inc

MBOTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.03

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.20Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $80.6M

Enterprise Value $77.4M

Shares Outstanding 67.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Microbot Medical Inc. has successfully transitioned from a clinical-stage research and development entity to a commercial-stage medical device company. The commercial launch of its LIBERTY® Endovascular Robotic System—the world's first single-use, remotely operated robotic solution for peripheral endovascular procedures—is gaining significant momentum. Following FDA clearance, the company recorded its first commercial revenue of $105,000 in Q1 2026 during its Limited Market Release (LMR). The subsequent transition to a Full Market Release (FMR) in Q2 2026 has already driven rapid account expansion, with mid-quarter revenue exceeding the entire first quarter. Backed by a robust liquidity profile of over $72 million in cash and marketable securities, Microbot is well-positioned to fund its commercial rollout, expand its federal footprint via its Lovell Government Services partnership, and secure international clearances, including its recent AMAR approval in Israel and pending CE Mark in Europe.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.00

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2015%

Commercial adoption of the LIBERTY system faces headwinds due to long hospital capital procurement cycles and clinical inertia. Tighter capital markets or higher-than-expected cash burn from sales and marketing expansion force the company to heavily utilize its ATM equity program, leading to substantial shareholder dilution. Regulatory delays push the European CE Mark timeline into late 2027, limiting near-term international growth.

Base CaseCentral scenario

$3.5060%

Microbot steadily expands its commercial footprint in the U.S., leveraging updated medical guidelines on occupational radiation and musculoskeletal protection to drive hospital adoption. Revenue grows sequentially quarter-over-quarter, supported by the Full Market Release and the Lovell partnership. International commercialization begins in Israel, and CE Mark preparation remains on track for late 2026/early 2027. The company's existing cash and marketable securities provide a comfortable runway of over 12 months to execute this launch phase.

Bull CaseUpside scenario

$5.0025%

Rapid commercial adoption of the LIBERTY system across both private hospital networks and federal healthcare systems (VHA, MHS, IHS) drives exponential revenue growth. The company successfully secures CE Mark approval by the end of 2026, opening up the massive European market ahead of schedule. High-margin disposable sales and recurring customer orders accelerate the path to operating break-even, while strategic partnerships or a potential acquisition by a major MedTech player unlock significant shareholder value.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Strong commercial momentum with Q2 2026 mid-quarter revenue already exceeding total Q1 2026 revenue due to a doubling of active accounts.
Robust liquidity position with $3.66M in cash and $68.84M in marketable securities as of March 31, 2026, providing a runway of over 12 months.
Strategic distribution agreement with Lovell Government Services, opening access to over 2,000 federal healthcare facilities.
Expanding international regulatory footprint, highlighted by the Israeli AMAR clearance in May 2026 and active pursuit of the European CE Mark.

Key Investment Risks

Early-stage commercial execution risk, with current revenues still small relative to ongoing operating losses ($3.67M net loss in Q1 2026).
Potential for equity dilution from active capital-raising programs, including the company's at-the-market (ATM) offering.
Dependence on third-party manufacturers and MedTech logistics providers to scale up production and manage inventory efficiently.
Risk of adoption delays from hospital value analysis committees (VAC) and long procurement cycles.

Thesis Invalidation Triggers

Failure to achieve meaningful sequential revenue growth in upcoming quarters, indicating commercial stagnation of the LIBERTY system.
Significant delays in obtaining the European CE Mark beyond the targeted end-of-2026 timeline.
A rapid acceleration in cash burn that depletes marketable securities faster than the projected 12-month runway, forcing highly dilutive financing.
Safety or efficacy issues arising from real-world clinical use of the LIBERTY system that lead to product recalls or regulatory warnings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.